Search Results
Results found for "Dongbo Bu"
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
Careers built on prestige, titles, or external pressure can burn out quickly. But careers built on urgency, alignment, and meaning are the ones that last. It was the first time late nights in the lab weren’t a burden but a sign of genuine engagement. Real-world data should guide how we build preclinical models.
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
Sharpen your discovery decisions ➤ Yamina’s Corner - The Hidden Cost of Busy A GPCR program can collapse—not Stop wasting talent: When senior leaders spend nights copy-pasting data, your burn rate accelerates
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
for GPCR scientists and translational teams, Premium keeps you informed on the science, careers, and business
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
For Catherine, those numbers aren’t just statistics—they’re signals guiding how to build better models
- Why “Displacement” Misleads You: Allosteric Binding Demystified
Terry’s Corner is built for scientists who want to move faster , think sharper , and make smarter decisions
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
She has a lot of experience working for bigger businesses which she now shares as an advisor for startups
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
Budded baculoviruses (BBV) have a high receptor concentration as well as being homogenous in size, which Using the FA method, CELT-419 binding affinity and kinetics were determined using budded baculovirus An equivalent volume of assay buffer was added to association controls (filled dark blue circles). Displacement of CELT-419 by different concentrations of Butaclamol (A) and PL-384 (B) at different M.; Bucolo, C.; Platania, C. B. M.; Salomone, S.; Drago, F.
- Exclusive Access: Terry's Corner is LIVE + Your Premium Member Discount!
This isn't just another lecture series; it's a practical tool designed to help you recognize and build
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
They’re hired for science, not for building operational scaffolding. Every two-week delay in a DMTA cycle can burn through hundreds of thousands in salaries and overhead. Build Precision Systems for GPCR Drug Discovery The only way out for GPCR drug discovery programs isn And if your systems aren’t built for precision, you’ll run out fast. 👉 In Part 2, we’ll expose exactly Let’s build the systems now, before the next delay burns another half a million. 🚀 Book your free 30
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Redefine Your Pipeline If your development program is built around potency alone, you may be leaving
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
As the lab grew, so did his responsibilities: from building computational models of GPCRs to guiding
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Sharpen your discovery decisions ➤ Yamina's Consulting Corner - Building Your GPCR Program for Breakthroughs Solve the problem of a fragmented approach by learning how to build a unified system where every scientific Three takeaways from this week’s feature: Stop firefighting: Learn why solving isolated problems burns Build predictable success: Use a repeatable improvement framework to turn operational chaos into precision
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry’s Corner is built to help you avoid those traps. Why now: GPCR research is accelerating—and the projects that succeed will be those built on clear, accurate
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
hours—not minutes—to equilibrate ✅ A framework for designing or troubleshooting allosteric modulators with built-in Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape future topics Built
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
If your pipeline is built only around extracellular engagement, you might be leaving opportunities untapped
- How Fast Does a Drug Work?
Outdated Models Slow Your Next Program The analytical tools that shaped traditional affinity assays were built
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs stall—not from bad data, but from buried decisions; Yamina's Corner helps teams cut through the noise and build clarity that drives action 🔹 Innovate faster → Celtarys’s newest GPCR tools Explore new screening tools purpose-built for
- Your GPCR Program Decisions Depend on Good Data Interpretation
: A Model for R&D Success Scientific rigor doesn’t thrive in cultures defined by micromanagement or burnout At Alkermes, Sokhom Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Your work belongs in the core conversation—not buried in supplementary files.
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Expand your computational toolkit ➤ Call for Papers: GPCRs: Signal Transduction, Volume II Building on
- From Venice to Virtual Molecules: Alessandro Nicoli’s Unexpected Journey into Computational Chemistry
While fascinated by organic chemistry and the idea of “building molecules,” he didn’t see the big picture—until Within weeks, he moved to Germany and became her first PhD student—helping build a lab from the ground limited ligand data, olfactory GPCRs represent a high-risk, high-reward challenge —perfect for a PhD built
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
Born in California and raised in Silicon Valley, his early interests were in finance and business. Building a Career from the Inside Out Now back in med school, Serafini aims to follow the physician-scientist
- Accelerating GPCR Drug Discovery
The GPCR Data Dilemma: The Lego Bucket Problem I've seen promising GPCR programs generate massive volumes I call this the Lego Bucket Problem . You have the data, but not the definitive direction. GPCR, we've built a global hub connecting over 1,300 GPCR scientists dedicated to this field. My Consulting Philosophy This practice is built on three core values: Scientific Integrity: Every Collaborative Partnership: I embed, contribute, and build solutions hand-in-hand with your team.
- From GPCR Data Chaos to Decisive Action
I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising Not possible when nothing’s built to surface the right insights early. That’s Why I Built Yamina’s Consulting Corner This is not “advising.” challenges firsthand, identify roadblocks faster , and i mplement solutions from within , ensuring genuine buy-in Operational Discipline ✔️ Collaborative Partnership Let’s Get Your GPCR Program Moving Again Whether you’re building
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
While others pivoted, Sokhom went deeper: refining assays, exploring signaling bias, and building a robust A Career Built on Consistency From CGRP receptor antagonists at BMS to opioid receptor research at Alkermes
- Pharmacology at Your Fingertips: Terry’s Corner Launches
Welcome Back, Discovery Drivers Terry’s Corner is live, on-demand pharmacology built for drug discovery That’s the Lego Bucket Problem.
- Signals in Motion: Pain, Metabolism & Terry’s Corner
HT1A agonist, delivers selective pain relief in preclinical models Dr.GPCR Updates Terry’s Corner – Build It’s a story of leadership, scientific rigor, and tools built for the needs of modern discovery teams CXCR4 signaling promotes terminal erythropoiesis through nuclear translocation and perinuclear calcium bursts
- Beyond the Probe: Scaling Innovation From the Bench to Product Launch
importance of genuinely listening to researchers: understanding the biological question first, then building
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
Explore her path from postdoc to platform builder.






























